SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank83
5Y CAGR-24.3%
Studio
Year-over-Year Change

Price-to-earnings ratio

5Y CAGR
-24.3%/yr
Long-term compound
Percentile
P83
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 yr
Consecutive growthElevated
PeriodValueYoY Change
20255.44+628.7%
2024-1.03-14.3%
2023-0.90+34.3%
2022-1.37+93.1%
2021-19.80-190.3%
202021.93+144.7%
2019-49.10-